Protocolo diagnóstico y terapéutico de la esteatosis hepática asociada a disfunción metabólica

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) refers to a broad spectrum of liver manifestations that range from simple steatosis, with a generally benign course, to forms with a higher risk of progression, such as hepatic steatosis or advanced liver disease phenotypes like cirrhosis or hepatocellular carcinoma. The global prevalence of MASLD is increasing in parallel to that of the metabolic syndrome, with the main groups at risk for the disease being patients with cardiometabolic comorbidity. Advances in non-invasive diagnostic techniques allow for identifying cases with a higher risk of progression and clinical events in these at-risk populations. The management of patients with MASLD is based on lifestyle modification. There are currently no drugs with an approved indication for the management of MASLD. Therefore, it is crucial to optimize the therapeutic management of metabolic syndrome and cardiovascular risk in these patients.